The debate over drug price negotiation policies, particularly those in the Inflation Reduction Act, has become the centerpiece of discussions about healthcare affordability, job creation, and innovation. Finding a balance between making lifesaving medications affordable while sustaining the incentives for innovation is critical.
Policy must consider the entire drug supply chain and take steps to avoid unintended consequences that may stifle job growth, impede future breakthroughs, and impact treatment.